In 2016, Bohm et al. published the OptiLink HF (Optimization of HF Management using OptiVolTM Fluid Status Monitoring and CareLinkTM) study [14], a prospective, multicenter, randomized, and unblinded study which included chronic HF patients in NYHA II-III with an ICD/CRTD device, and either prior HF hospitalization, recent diuretic treatment, or recent BNP increase. The gene discussed is NPPB; the disease is hydrops fetalis.